Wall Street analysts forecast that MAXIMUS, Inc. (NYSE:MMS) will report earnings of $0.95 per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for MAXIMUS’s earnings, with the highest EPS estimate coming in at $0.99 and the lowest estimate coming in at $0.92. MAXIMUS posted earnings per share of $0.73 during the same quarter last year, which indicates a positive year over year growth rate of 30.1%. The business is expected to issue its next quarterly earnings report on Tuesday, November 19th.
According to Zacks, analysts expect that MAXIMUS will report full year earnings of $3.73 per share for the current year, with EPS estimates ranging from $3.70 to $3.75. For the next financial year, analysts anticipate that the business will post earnings of $4.10 per share, with EPS estimates ranging from $4.01 to $4.14. Zacks’ earnings per share averages are an average based on a survey of research firms that follow MAXIMUS.
MAXIMUS (NYSE:MMS) last issued its quarterly earnings results on Thursday, August 8th. The health services provider reported $0.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.93 by $0.04. MAXIMUS had a net margin of 8.44% and a return on equity of 20.72%. The company had revenue of $730.70 million during the quarter, compared to analyst estimates of $754.81 million. During the same quarter last year, the business posted $0.91 EPS. MAXIMUS’s quarterly revenue was up 22.2% compared to the same quarter last year.
MMS has been the subject of several research analyst reports. Wells Fargo & Co restated a “market perform” rating and set a $83.00 price target on shares of MAXIMUS in a research note on Friday, August 9th. ValuEngine cut shares of MAXIMUS from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Canaccord Genuity lifted their target price on shares of MAXIMUS from $72.00 to $77.00 and gave the stock a “hold” rating in a research report on Tuesday. Finally, Zacks Investment Research upgraded shares of MAXIMUS from a “hold” rating to a “buy” rating and set a $75.00 target price on the stock in a research report on Monday, May 27th.
Shares of MMS stock traded up $1.45 during trading hours on Friday, hitting $77.37. 271,300 shares of the company were exchanged, compared to its average volume of 306,149. The firm has a fifty day simple moving average of $73.84 and a 200 day simple moving average of $72.44. MAXIMUS has a 52-week low of $60.00 and a 52-week high of $80.83. The stock has a market capitalization of $4.84 billion, a price-to-earnings ratio of 22.76, a P/E/G ratio of 2.03 and a beta of 0.88.
The business also recently declared a quarterly dividend, which will be paid on Friday, August 30th. Investors of record on Thursday, August 15th will be given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.29%. The ex-dividend date of this dividend is Wednesday, August 14th. MAXIMUS’s dividend payout ratio is currently 29.41%.
In related news, Vice Chairman Richard A. Montoni sold 12,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $74.07, for a total transaction of $888,840.00. Following the sale, the insider now owns 377,874 shares of the company’s stock, valued at $27,989,127.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Vice Chairman Richard A. Montoni sold 35,000 shares of the business’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $74.68, for a total transaction of $2,613,800.00. Following the sale, the insider now directly owns 377,874 shares in the company, valued at approximately $28,219,630.32. The disclosure for this sale can be found here. Insiders have sold 48,000 shares of company stock worth $3,575,540 in the last quarter. 2.20% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. 6 Meridian boosted its stake in MAXIMUS by 2.3% during the second quarter. 6 Meridian now owns 7,045 shares of the health services provider’s stock worth $511,000 after acquiring an additional 157 shares in the last quarter. Signaturefd LLC lifted its stake in shares of MAXIMUS by 19.6% in the second quarter. Signaturefd LLC now owns 1,145 shares of the health services provider’s stock worth $83,000 after buying an additional 188 shares in the last quarter. Chatham Capital Group Inc. lifted its stake in shares of MAXIMUS by 0.7% in the first quarter. Chatham Capital Group Inc. now owns 32,850 shares of the health services provider’s stock worth $2,332,000 after buying an additional 241 shares in the last quarter. Cambiar Investors LLC lifted its stake in shares of MAXIMUS by 0.4% in the second quarter. Cambiar Investors LLC now owns 70,399 shares of the health services provider’s stock worth $5,107,000 after buying an additional 256 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of MAXIMUS by 0.4% in the second quarter. First Trust Advisors LP now owns 72,679 shares of the health services provider’s stock worth $5,272,000 after buying an additional 273 shares in the last quarter. 94.53% of the stock is currently owned by institutional investors and hedge funds.
MAXIMUS, Inc provides business process services (BPS) to government health and human services programs worldwide. The company's Health Services segment offers various BPS, appeals, and assessments for state, provincial, and national government programs, including Medicaid, Children's Health Insurance Program, Affordable Care Act, Health Insurance British Columbia, Health Assessment Advisory Service contract, and Preadmission Screening and Resident Reviews.
Further Reading: How much money do you need to begin day trading?
Get a free copy of the Zacks research report on MAXIMUS (MMS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.